Lorestani Parsa, Dashti Mohsen, Nejati Negar, Habibi Mohammad Amin, Askari Mandana, Robat-Jazi Behruz, Ahmadpour Sajjad, Tavakolpour Soheil
Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Discov Oncol. 2024 Aug 26;15(1):369. doi: 10.1007/s12672-024-01256-x.
Pancreatic cancer (PC) is one of the deadliest cancers worldwide with low survival rates and poor outcomes. The treatment landscape for PC is fraught with obstacles, including drug resistance, lack of effective targeted therapies and the immunosuppressive tumor microenvironment (TME). The resistance of PC to existing immunotherapies highlights the need for innovative approaches, with the TME emerging as a promising therapeutic target. The recent advancements in understanding the role of macrophages, this context highlight their significant impact on tumor development and progression. There are two important types of macrophages: M1 and M2, which play critical roles in the TME. Therapeutics strategies including, depletion of tumor-associated macrophages (TAMs), reprogramming TAMs to promote anti-tumor activity, and targeting macrophage recruitment can lead to promising outcomes. Targeting macrophage-related pathways may offer novel strategies for modulating immune responses, inhibiting angiogenesis, and overcoming resistance to chemotherapy in PC treatment.
胰腺癌（PC）是全球最致命的癌症之一，生存率低且预后不佳。PC的治疗前景充满障碍，包括耐药性、缺乏有效的靶向治疗以及免疫抑制性肿瘤微环境（TME）。PC对现有免疫疗法的耐药性凸显了创新方法的必要性，TME成为一个有前景的治疗靶点。近期在理解巨噬细胞作用方面取得的进展，突显了它们在肿瘤发生和进展中的重大影响。巨噬细胞有两种重要类型：M1和M2，它们在TME中发挥关键作用。治疗策略包括清除肿瘤相关巨噬细胞（TAM）、将TAM重编程以促进抗肿瘤活性以及靶向巨噬细胞募集，可能会带来有前景的结果。靶向与巨噬细胞相关的通路可能为调节免疫反应、抑制血管生成以及克服PC治疗中的化疗耐药性提供新策略。
